All In Biotech

Investigational drug · Phase 2

BCD-236

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Triple Negative Breast Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "BCD-236"

First trial start

2024

Jul 15, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BCD-236", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Triple Negative Breast Cancer

Approved drugs for the same conditions: Breast cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "BCD-236" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Triple Negative Breast Cancer

  • SerplulimabHLX10, HLX43Phase 325 trials

    Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage

  • LBL-024Phase 311 trials

    Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma

  • JSKN016Phase 34 trials

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer

  • OBI-821OBI-833Phase 32 trials

    OBI Pharma, Inc · Triple Negative Breast Cancer, Non-small Cell Lung Cancer

  • FDA018-ADCPhase 31 trial

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Triple Negative Breast Cancer

  • IL-2MDNA11, Interleukin-2 -albuminPhase 24 trials

    Grit Biotechnology · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma

  • BT5528nuzefatide pevedotinPhase 23 trials

    BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer

  • BLEX 404 LiquidPhase 22 trials

    BioLite, Inc. · Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.